▁Introduction 7.82421875
: 1.9072265625
<0x0A> 6.53125
In 3.4140625
▁the 1.5205078125
▁ever 7.2109375
- 0.423095703125
ad 5.66796875
van 0.010833740234375
cing 0.002910614013671875
▁field 2.318359375
▁of 0.00695037841796875
▁cancer 5.43359375
▁research 1.1875
, 0.1341552734375
▁British 11.9609375
▁Bi 6.16796875
ote 0.324462890625
ch 0.1741943359375
' 3.931640625
s 0.0014524459838867188
▁revolution 5.95703125
ary 0.00870513916015625
▁anti 4.2421875
- 0.043548583984375
can 0.60546875
cer 0.000392913818359375
▁treatment 3.232421875
▁Mar 9.578125
im 4.89453125
ast 0.018157958984375
at 5.5909156799316406e-05
▁has 1.59765625
▁gar 4.91015625
ner 0.0001895427703857422
ed 0.0003273487091064453
▁significant 2.001953125
▁attention 0.355712890625
▁and 2.2421875
▁now 8.3203125
▁stands 1.9384765625
▁at 1.390625
▁a 3.787109375
▁critical 1.560546875
▁jun 0.5859375
ct 8.404254913330078e-05
ure 3.2782554626464844e-05
. 0.89453125
▁As 3.048828125
▁anal 8.78125
yst 0.03070068359375
s 0.065185546875
▁and 1.357421875
▁exper 1.8916015625
ts 9.381771087646484e-05
▁eager 5.36328125
ly 0.0005898475646972656
▁anticip 1.2490234375
ate 0.0027866363525390625
▁the 0.29638671875
▁latest 3.177734375
▁develop 1.4375
ments 0.0001049041748046875
▁at 5.55078125
▁the 0.57373046875
▁European 4.1484375
▁Society 0.8515625
▁for 0.42919921875
▁Medical 0.0308990478515625
▁On 0.0020275115966796875
col 0.0018224716186523438
ogy 5.519390106201172e-05
▁( 0.401611328125
ES 0.005962371826171875
MO 0.00013184547424316406
) 0.041229248046875
▁meeting 2.9921875
, 0.79833984375
▁all 5.69921875
▁eyes 0.031829833984375
▁are 0.25341796875
▁on 0.154296875
▁the 0.78662109375
▁un 5.1328125
ve 0.51904296875
iling 0.0017442703247070312
▁of 0.007244110107421875
▁new 2.0390625
▁evidence 4.515625
▁on 2.27734375
▁Mar 1.0302734375
im 0.0023670196533203125
ast 0.0005917549133300781
at 0.0016813278198242188
' 0.28759765625
s 0.0011281967163085938
▁effic 1.1240234375
acy 7.319450378417969e-05
, 3.216796875
▁potential 3.755859375
▁side 3.009765625
▁effects 0.044677734375
, 0.2091064453125
▁and 0.0604248046875
▁its 3.083984375
▁promise 5.5546875
▁in 2.15234375
▁the 1.173828125
▁battle 2.126953125
▁against 0.00594329833984375
▁cancer 0.1756591796875
. 0.0207061767578125
<0x0A> 0.36962890625
Background 4.515625
: 0.1990966796875
<0x0A> 9.375
Mar 1.365234375
im 0.0006866455078125
ast 8.285045623779297e-05
at 0.0001329183578491211
, 1.0205078125
▁a 0.91943359375
▁ground 6.33984375
bre 0.3095703125
aking 1.0967254638671875e-05
▁drug 2.03515625
▁developed 0.59423828125
▁by 0.022216796875
▁British 0.0289459228515625
▁Bi 0.0049591064453125
ote 0.0002968311309814453
ch 0.0014200210571289062
, 0.070556640625
▁has 0.5302734375
▁shown 2.60546875
▁promise 2.66796875
▁in 0.07586669921875
▁in 5.44921875
hib 0.01922607421875
iting 0.0013675689697265625
▁the 0.65087890625
▁growth 0.7021484375
▁of 0.297119140625
▁cancer 0.78173828125
ous 2.298828125
▁tum 0.6689453125
ors 0.06829833984375
. 0.90283203125
▁By 4.30859375
▁target 0.90185546875
ing 0.0004165172576904297
▁Matrix 6.7578125
▁Metal 0.12225341796875
lo 0.0003497600555419922
prote 0.022918701171875
in 0.025054931640625
ases 1.126953125
▁( 0.09332275390625
M 0.00543975830078125
MP 6.783008575439453e-05
s 0.05206298828125
), 0.09649658203125
▁en 4.58984375
zym 0.00017058849334716797
es 0.0011196136474609375
▁that 0.371337890625
▁promote 3.0234375
▁cancer 1.4140625
▁cell 0.345947265625
▁growth 0.487060546875
▁and 0.41015625
▁met 1.984375
ast 0.0016202926635742188
asis 0.01120758056640625
, 0.005992889404296875
▁Mar 0.100830078125
im 0.000850677490234375
ast 8.082389831542969e-05
at 0.00030350685119628906
▁a 4.2734375
ims 0.051727294921875
▁to 0.000606536865234375
▁dis 1.9970703125
rupt 0.005573272705078125
▁tum 3.541015625
or 0.043975830078125
▁pro 1.4814453125
gression 0.02947998046875
▁and 0.272705078125
▁potentially 2.810546875
▁improve 1.541015625
▁patient 0.38134765625
▁out 0.083740234375
comes 4.2438507080078125e-05
. 0.016998291015625
▁Initial 7.23828125
▁studies 1.0068359375
▁have 0.25634765625
▁show 7.95703125
c 0.05316162109375
ased 0.00010919570922851562
▁its 1.857421875
▁potential 2.255859375
▁in 1.7001953125
▁various 1.9990234375
▁cancer 0.615234375
▁types 0.05712890625
, 0.108154296875
▁including 0.4658203125
▁breast 1.2626953125
, 0.292236328125
▁li 6.6640625
ver 5.3048133850097656e-05
, 0.0163116455078125
▁and 0.455322265625
▁pro 2.17578125
state 0.0028133392333984375
▁cancer 0.6181640625
. 0.5185546875
<0x0A> 0.314697265625
ES 3.02734375
MO 0.0015077590942382812
▁Me 1.275390625
eting 0.0046539306640625
: 0.23779296875
▁An 6.58203125
▁O 0.472412109375
pport 0.0020656585693359375
unity 0.001651763916015625
▁for 1.05859375
▁Break 2.033203125
through 0.00022292137145996094
s 0.306640625
: 0.640625
<0x0A> 0.03778076171875
The 0.521484375
▁eager 7.7421875
ly 0.0192718505859375
▁anticip 0.480224609375
ated 0.0017576217651367188
▁ES 0.24462890625
MO 4.0531158447265625e-05
▁meeting 0.06787109375
, 1.6103515625
▁one 5.68359375
▁of 0.0028514862060546875
▁the 0.01983642578125
▁most 0.865234375
▁prominent 2.599609375
▁global 3.990234375
▁con 1.6611328125
ferences 0.02447509765625
▁on 1.1611328125
▁cancer 0.3564453125
▁research 0.418701171875
▁and 1.470703125
▁ther 3.419921875
ap 0.95458984375
ies 0.00018012523651123047
, 0.0092315673828125
▁presents 2.341796875
▁a 0.435791015625
▁valuable 3.880859375
▁platform 0.78857421875
▁for 0.076171875
▁British 0.490966796875
▁Bi 0.002109527587890625
ote 8.20159912109375e-05
ch 0.0009760856628417969
▁to 0.0682373046875
▁show 0.95068359375
case 0.0003924369812011719
▁the 1.48046875
▁latest 0.23388671875
▁evidence 1.7158203125
▁on 0.2459716796875
▁Mar 0.06219482421875
im 0.0007505416870117188
ast 0.0003674030303955078
at 0.0003459453582763672
. 1.447265625
▁Research 4.86328125
ers 0.039337158203125
, 1.2314453125
▁on 1.802734375
colog 0.0100860595703125
ists 0.0002071857452392578
, 0.0023212432861328125
▁and 0.039520263671875
▁anal 4.21875
yst 0.0001347064971923828
s 0.00036454200744628906
▁are 2.080078125
▁looking 4.3125
▁forward 0.12286376953125
▁to 0.0016336441040039062
▁gain 2.34765625
ing 0.00891876220703125
▁ins 0.7109375
ights 8.177757263183594e-05
▁into 0.1748046875
▁the 0.2266845703125
▁drug 0.4501953125
' 0.006099700927734375
s 9.763240814208984e-05
▁progress 4.78515625
▁in 2.716796875
▁clin 0.56982421875
ical 0.00016772747039794922
▁tri 0.0237274169921875
als 8.940696716308594e-06
, 0.7158203125
▁further 6.58203125
▁patient 6.94140625
▁response 7.3203125
▁data 0.74267578125
, 0.035980224609375
▁and 0.042388916015625
▁potential 1.53515625
▁ref 6.59765625
in 0.01074981689453125
ements 0.07904052734375
▁that 3.33203125
▁may 1.146484375
▁improve 1.5576171875
▁its 0.5576171875
▁effect 2.220703125
iveness 0.0012044906616210938
. 0.58203125
<0x0A> 0.10992431640625
E 3.150390625
ffic 1.0205078125
acy 0.004581451416015625
▁and 0.492431640625
▁Saf 1.9169921875
ety 6.0677528381347656e-05
: 0.58251953125
▁Key 3.59375
▁F 1.4384765625
ocus 0.0097198486328125
▁Are 0.68017578125
as 1.609325408935547e-05
: 0.24853515625
<0x0A> 0.00951385498046875
Anal 4.29296875
yst 0.056915283203125
s 0.005031585693359375
▁will 3.80078125
▁closely 1.63671875
▁examine 1.6982421875
▁the 0.406005859375
▁effic 0.5205078125
acy 1.1563301086425781e-05
▁of 2.099609375
▁Mar 0.01374053955078125
im 0.0004832744598388672
ast 6.592273712158203e-05
at 0.0001595020294189453
, 1.6171875
▁seeking 4.49609375
▁evidence 1.5126953125
▁on 2.560546875
▁its 0.1710205078125
▁ability 0.587890625
▁to 0.00019037723541259766
▁in 0.89453125
hib 8.893013000488281e-05
it 4.851818084716797e-05
▁M 1.123046875
MP 0.0004239082336425781
s 0.1688232421875
▁effectively 4.2421875
. 2.875
▁D 7.08203125
etailed 0.1834716796875
▁results 4.23046875
▁from 1.015625
▁pre 4.97265625
cl 0.489013671875
in 2.0503997802734375e-05
ical 7.402896881103516e-05
▁and 0.472412109375
▁early 3.30078125
- 0.54638671875
stage 0.448486328125
▁clin 0.1561279296875
ical 6.568431854248047e-05
▁tri 0.05938720703125
als 6.079673767089844e-06
▁will 0.59228515625
▁provide 1.8837890625
▁a 2.087890625
▁vital 5.31640625
▁understanding 1.8642578125
▁of 0.0060882568359375
▁the 0.412353515625
▁drug 0.05255126953125
' 0.0015230178833007812
s 7.295608520507812e-05
▁impact 3.1953125
▁on 0.06390380859375
▁tum 1.0419921875
or 0.0274505615234375
▁growth 0.57470703125
, 1.390625
▁pro 1.919921875
gression 0.0264129638671875
, 0.005855560302734375
▁and 0.005908966064453125
▁disease 7.27734375
- 2.19921875
free 0.040130615234375
▁surv 0.048065185546875
ival 0.0011854171752929688
▁rates 1.4541015625
▁in 3.439453125
▁different 1.96484375
▁cancer 0.5166015625
▁types 0.0545654296875
. 0.017333984375
▁Moreover 3.564453125
, 0.0002416372299194336
▁with 5.46484375
▁safety 3.1796875
▁being 0.654296875
▁a 0.130126953125
▁significant 2.484375
▁concern 0.25634765625
, 1.515625
▁anal 1.115234375
yst 0.0002300739288330078
s 0.0007271766662597656
▁will 0.133544921875
▁scr 1.2705078125
ut 5.125999450683594e-06
in 0.00015354156494140625
ize 0.003997802734375
▁any 1.220703125
▁evidence 4.46484375
▁of 0.356689453125
▁ad 1.1455078125
verse 4.887580871582031e-06
▁side 1.857421875
▁effects 0.0026874542236328125
▁associated 2.71484375
▁with 0.0002532005310058594
▁Mar 0.3466796875
im 0.0003657341003417969
ast 0.00010502338409423828
at 9.393692016601562e-05
▁usage 4.68359375
. 0.2388916015625
<0x0A> 0.053466796875
P 2.76953125
ot 0.037353515625
ential 0.0033111572265625
▁Market 4.59375
▁Imp 0.81005859375
act 0.2322998046875
: 0.09722900390625
<0x0A> 0.32861328125
The 0.90576171875
▁impact 3.333984375
▁of 0.0273590087890625
▁Mar 0.2003173828125
im 0.0003783702850341797
ast 0.00010120868682861328
at 7.617473602294922e-05
▁on 0.73046875
▁the 0.052978515625
▁ph 3.462890625
arma 0.0027675628662109375
ce 0.01409149169921875
ut 1.1920928955078125e-07
ical 8.296966552734375e-05
▁market 1.1796875
▁could 3.154296875
▁be 0.04736328125
▁substantial 2.66015625
, 0.578125
▁given 2.37890625
▁its 0.20556640625
▁potential 0.454833984375
▁as 2.650390625
▁a 0.160888671875
▁novel 1.9638671875
▁treatment 1.7978515625
▁option 0.369873046875
. 2.8125
▁Anal 1.4345703125
yst 0.002925872802734375
s 0.0016412734985351562
▁are 2.00390625
▁particularly 4.015625
▁interested 0.347900390625
▁in 0.02239990234375
▁its 2.529296875
▁compet 4.90625
itive 0.12042236328125
▁advantages 2.806640625
▁over 0.94775390625
▁existing 0.47412109375
▁treatment 4.06640625
▁modal 3.41796875
ities 1.6689300537109375e-05
▁and 1.2822265625
▁the 1.748046875
▁potential 0.71875
▁market 4.26953125
▁position 5.3515625
ing 0.7158203125
▁of 1.181640625
▁the 0.6181640625
▁drug 0.032196044921875
. 1.146484375
▁Additionally 2.765625
, 0.00011432170867919922
▁they 1.8330078125
▁await 8.0859375
▁ins 1.873046875
ights 0.00014019012451171875
▁into 0.340576171875
▁the 0.54443359375
▁drug 1.001953125
' 0.00972747802734375
s 5.984306335449219e-05
▁manufact 3.998046875
uring 0.00687408447265625
▁scal 5.6015625
ability 0.00024771690368652344
▁and 0.6240234375
▁pr 2.951171875
icing 3.612041473388672e-05
▁strateg 1.4423828125
ies 3.4689903259277344e-05
, 0.44873046875
▁which 0.27783203125
▁could 0.56640625
▁influence 1.6630859375
▁its 0.247314453125
▁avail 4.70703125
ability 6.115436553955078e-05
▁and 0.21728515625
▁access 1.08984375
ibility 0.006626129150390625
▁to 0.77392578125
▁patients 0.145263671875
▁across 4.41796875
▁the 0.974609375
▁glo 0.234619140625
be 2.09808349609375e-05
. 0.005611419677734375
<0x0A> 0.022216796875
Imp 4.625
lications 0.345458984375
▁for 0.10650634765625
▁Can 1.0263671875
cer 1.1444091796875e-05
▁Pat 1.3896484375
ients 0.0193634033203125
: 0.11590576171875
<0x0A> 0.027862548828125
Mar 3.408203125
im 0.00027561187744140625
ast 2.7418136596679688e-05
at 7.271766662597656e-05
' 0.30810546875
s 7.414817810058594e-05
▁effic 2.90234375
acy 7.62939453125e-06
▁in 2.306640625
▁in 0.90185546875
hib 4.565715789794922e-05
iting 0.00014543533325195312
▁M 0.436279296875
MP 0.00014531612396240234
s 0.0275421142578125
▁not 6.81640625
▁only 0.017303466796875
▁provides 3.830078125
▁hope 1.310546875
▁for 0.0819091796875
▁patients 1.658203125
▁currently 5.3046875
▁batt 1.861328125
ling 0.00024402141571044922
▁cancer 0.06195068359375
▁but 0.48193359375
▁could 3.041015625
▁potentially 2.57421875
▁offer 4.53515625
▁an 3.078125
▁alternative 0.418701171875
▁to 1.0107421875
▁invas 3.962890625
ive 3.349781036376953e-05
▁and 1.328125
▁ag 3.9921875
gress 0.0037288665771484375
ive 0.00011539459228515625
▁treatment 0.85009765625
▁approaches 2.93359375
. 0.220703125
▁Depending 8.078125
▁on 0.004871368408203125
▁the 0.1314697265625
▁evidence 3.30078125
▁presented 0.4501953125
▁at 0.13330078125
▁the 0.268798828125
▁ES 0.222900390625
MO 6.4849853515625e-05
▁meeting 0.0238800048828125
, 0.02685546875
▁Mar 1.693359375
im 0.0005054473876953125
ast 0.0001341104507446289
at 8.058547973632812e-05
▁may 1.4541015625
▁p 3.55859375
ave 0.0009288787841796875
▁the 0.006290435791015625
▁way 0.0029926300048828125
▁for 0.018218994140625
▁personal 3.162109375
ized 0.0008568763732910156
▁cancer 1.3671875
▁ther 1.03125
ap 0.2161865234375
ies 3.1828880310058594e-05
▁that 0.84765625
▁target 1.017578125
▁individual 2.51953125
▁cancer 2.09375
▁types 0.56884765625
▁more 2.33984375
▁precisely 1.75
, 1.33203125
▁potentially 2.328125
▁transform 4.953125
ing 0.00029540061950683594
▁the 0.5341796875
▁landscape 1.314453125
▁of 0.0089263916015625
▁cancer 0.0750732421875
▁treatment 0.818359375
. 0.31396484375
<0x0A> 0.088623046875
Con 1.919921875
clusion 0.09722900390625
: 0.007755279541015625
<0x0A> 2.830078125
The 0.98046875
▁release 7.30078125
▁of 0.00983428955078125
▁new 0.5263671875
▁evidence 0.3818359375
▁on 0.23486328125
▁Mar 0.0693359375
im 0.0006546974182128906
ast 5.424022674560547e-05
at 6.794929504394531e-05
▁at 1.1357421875
▁the 0.058990478515625
▁forth 3.4765625
coming 1.5139579772949219e-05
▁ES 0.0487060546875
MO 4.208087921142578e-05
▁meeting 0.0265960693359375
▁has 2.6953125
▁spark 2.17578125
ed 1.990795135498047e-05
▁immense 2.87109375
▁anticip 1.798828125
ation 0.00010979175567626953
▁among 0.90234375
▁on 3.05859375
col 2.5078125
ogy 3.9696693420410156e-05
▁exper 0.76513671875
ts 5.125999450683594e-06
, 0.85693359375
▁anal 0.6826171875
yst 1.7881393432617188e-05
s 9.083747863769531e-05
, 0.0023593902587890625
▁and 0.01171112060546875
▁patients 0.71337890625
▁al 1.0625
ike 3.2186508178710938e-06
. 0.01666259765625
▁This 3.73828125
▁ground 2.333984375
bre 0.06500244140625
aking 2.2649765014648438e-06
▁drug 0.771484375
▁developed 7.1484375
▁by 0.0010271072387695312
▁British 0.0022602081298828125
▁Bi 0.0016002655029296875
ote 4.017353057861328e-05
ch 0.0002894401550292969
▁has 0.99658203125
▁the 0.58935546875
▁potential 0.003143310546875
▁to 0.0013265609741210938
▁revolution 0.65771484375
ize 0.0006146430969238281
▁cancer 0.487548828125
▁treatment 0.2274169921875
▁by 2.22265625
▁in 1.26171875
hib 2.9206275939941406e-05
iting 5.7697296142578125e-05
▁tum 2.47265625
or 0.006580352783203125
▁growth 0.55859375
▁effectively 5.7734375
. 1.4990234375
▁As 1.31640625
▁the 1.0908203125
▁world 1.705078125
▁a 1.806640625
wa 0.00031757354736328125
its 0.00011754035949707031
▁the 0.210205078125
▁latest 0.453369140625
▁data 3.224609375
, 1.115234375
▁the 1.6083984375
▁results 5.87890625
▁may 3.15625
▁p 3.3515625
ave 0.00019466876983642578
▁the 0.00254058837890625
▁way 0.0052642822265625
▁for 0.0146331787109375
▁a 1.29296875
▁new 0.6435546875
▁era 0.1483154296875
▁of 0.49267578125
▁personal 0.26025390625
ized 0.0004367828369140625
▁cancer 0.2783203125
▁ther 0.194580078125
ap 0.0916748046875
ies 1.2636184692382812e-05
▁and 1.96875
▁offer 2.265625
▁renew 3.548828125
ed 1.537799835205078e-05
▁hope 0.0084381103515625
▁to 0.60302734375
▁millions 2.564453125
▁of 0.1441650390625
▁patients 1.154296875
▁batt 1.8662109375
ling 0.00018644332885742188
▁this 1.0078125
▁dead 2.044921875
ly 0.0001354217529296875
▁disease 0.004009246826171875
. 0.05877685546875
